Nanexa 관리

관리 기준 확인 4/4

Nanexa CEO는 David Westberg, Jan2015 에 임명되었습니다 의 임기는 9.83 년입니다. 총 연간 보상은 SEK 2.85M, 78.4% 로 구성됩니다. 78.4% 급여 및 21.6% 보너스(회사 주식 및 옵션 포함). 는 SEK 579.04K 가치에 해당하는 회사 주식의 0.27% 직접 소유합니다. 579.04K. 경영진과 이사회의 평균 재임 기간은 각각 9.8 년과 3.5 년입니다.

주요 정보

David Westberg

최고 경영자

SEK 2.8m

총 보상

CEO 급여 비율	78.4%
CEO 임기	9.8yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	9.8yrs
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

How Much Does Nanexa's (STO:NANEXA) CEO Make?

Dec 09

CEO 보상 분석

David Westberg 의 보수는 Nanexa 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 64m
Jun 30 2024	n/a	n/a	-SEK 67m
Mar 31 2024	n/a	n/a	-SEK 71m
Dec 31 2023	SEK 3m	SEK 2m	-SEK 76m
Sep 30 2023	n/a	n/a	-SEK 43m
Jun 30 2023	n/a	n/a	-SEK 49m
Mar 31 2023	n/a	n/a	-SEK 55m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 59m
Sep 30 2022	n/a	n/a	-SEK 54m
Jun 30 2022	n/a	n/a	-SEK 50m
Mar 31 2022	n/a	n/a	-SEK 42m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 36m
Sep 30 2021	n/a	n/a	-SEK 31m
Jun 30 2021	n/a	n/a	-SEK 27m
Mar 31 2021	n/a	n/a	-SEK 25m
Dec 31 2020	SEK 3m	SEK 2m	-SEK 22m
Sep 30 2020	n/a	n/a	-SEK 19m
Jun 30 2020	n/a	n/a	-SEK 18m
Mar 31 2020	n/a	n/a	-SEK 13m
Dec 31 2019	SEK 2m	SEK 1m	-SEK 13m
Sep 30 2019	n/a	n/a	-SEK 12m
Jun 30 2019	n/a	n/a	-SEK 11m
Mar 31 2019	n/a	n/a	-SEK 12m
Dec 31 2018	SEK 2m	SEK 1m	-SEK 11m
Sep 30 2018	n/a	n/a	-SEK 9m
Jun 30 2018	n/a	n/a	-SEK 9m
Mar 31 2018	n/a	n/a	-SEK 8m
Dec 31 2017	SEK 1m	SEK 1m	-SEK 8m

보상 대 시장: David 의 총 보상 ($USD 258.83K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 236.52K ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

David Westberg (64 yo)

9.8yrs

테뉴어

SEK 2,847,000

보상

Mr. David Westberg has been the Chief Executive Officer at Nanexa AB (publ) since 2015. Mr. Westberg serves as an Independent Director at Lipigon Pharmaceuticals AB (publ) since 2023. Mr. Westberg has expe...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Westberg	Chief Executive Officer	9.8yrs	SEK 2.85m	0.27% SEK 558.6k
Marten Rooth	Co-Founder	15.8yrs	데이터 없음	0.33% SEK 665.2k
Anders Johansson	Co-Founder & Head of Intellectual Property	15.8yrs	SEK 996.00k	0.30% SEK 617.4k
Cecilia Danckwardt-Lilliestrom	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Mikael Asp	Head of QA & Expert Sakkunnig	4.4yrs	데이터 없음	0.0027% SEK 5.5k
Joel Hellrup	Head of Pharmaceutical R&D	no data	데이터 없음	0.0052% SEK 10.5k

9.8yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: NANEXA 의 관리팀은 노련하고 경험 (평균 재직 기간 9.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Birgit Norinder	Independent Director	3.5yrs	SEK 180.00k	0.044% SEK 90.3k
Goran Ando	Independent Chairman of the Board	4.8yrs	SEK 260.00k	0.77% SEK 1.6m
Robert Gale	Member of Advisory Board - NEX-18	no data	데이터 없음	데이터 없음
Eva Nilsagard	Independent Director	3.5yrs	SEK 230.00k	0.13% SEK 270.9k
Magnus Westgren	Independent Director	9.8yrs	SEK 130.00k	0.19% SEK 382.5k
Axel Glasmacher	Member of Advisory Board - NEX-18 & NEX-20	no data	데이터 없음	데이터 없음
Richard Davis	Independent Director	2.4yrs	SEK 130.00k	데이터 없음
Kirsten Gronbaek	Member of Advisory Board - NEX-18	no data	데이터 없음	데이터 없음
Uwe Platzbecker	Member of Advisory Board - NEX-18	no data	데이터 없음	데이터 없음
Magnus Tobiasson	Member of Advisory Board - NEX-18	no data	데이터 없음	데이터 없음
Jose Miguel Diaz	Member of Advisory Board - NEX-18	no data	데이터 없음	데이터 없음
Xavier Leleu	Member of Advisory Board - NEX-20	no data	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: NANEXA 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

Nanexa 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

Less than half of directors are independent

Recent updates

Nanexa AB Announces Positive Results in the Phase I Study for NEX-22, Long Acting GLP-1, in Type 2 Diabetes

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.11 loss in 3Q 2023)

Nanexa AB (Publ) Completes Phase I Trial of NEX-22 in Type 2 Diabetes

New minor risk - Revenue size

Nanexa AB (Publ) Announces That the First Patient in the Third Dose Group with Their Long-Acting Depot Formulation of the Glp-1 Analog Liraglutide Has Been Dosed

New minor risk - Profitability

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.16 loss in 2Q 2023)

Nanexa's Phase I Trial of NEX-22 in Type 2- Diabetes Progresses with Next Dose Group According to Plan

Nanexa AB (publ) Announces Chief Financial Officer Changes

Nanexa AB (Publ) Announces That First Patient Dosed in Nanexa's Phase I Trial of NEX-22 in Type 2 Diabetes

New major risk - Financial position

Nanexa AB Receives Approval for NEX-22 Clinical Study

Nanexa AB (publ) Elects Hanna Tilus as Members of the Board

First quarter 2024 earnings released: kr0.02 loss per share (vs kr0.14 loss in 1Q 2023)

Nanexa AB (publ) Announces Approval of Clinical Trial Application for NEX-22 Study Delayed

New major risk - Shareholder dilution

Full year 2023 earnings released: kr1.09 loss per share (vs kr1.16 loss in FY 2022)

Nanexa AB (publ), Annual General Meeting, May 15, 2024

Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA

Consensus revenue estimates increase by 32%

New minor risk - Financial position

Third quarter 2023 earnings released: kr0.11 loss per share (vs kr0.24 loss in 3Q 2022)

Nanexa AB Completes Clinical Phase I Study with NEX-20

Consensus EPS estimates upgraded to kr0.42 loss

Price target decreased by 19% to kr4.95

Second quarter 2023 earnings released: kr0.16 loss per share (vs kr0.32 loss in 2Q 2022)

Nanexa AB Confirms Continued Positive Results from A New Preclinical Study of Nex-22

Nanexa AB (Publ) Approves Election of Jakob Dynnes Hansen as Member of the Board

Nanexa AB (Publ) Announces Urban Paulsson and Bengt Gustavsson Declines Re-Election

First quarter 2023 earnings released: kr0.14 loss per share (vs kr0.24 loss in 1Q 2022)

Nanexa AB (publ) to Report Q1, 2023 Results on May 04, 2023

Full year 2022 earnings released: kr1.16 loss per share (vs kr1.01 loss in FY 2021)

Nanexa AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Nanexa Starts the Phase 1 Study of NEX-20 According to Plan

Price target decreased to kr6.00

No longer forecast to breakeven

Nanexa Receives Approval to Start Clinical Trial with NEX-20

Third quarter 2022 earnings released: kr0.24 loss per share (vs kr0.18 loss in 3Q 2021)

Nanexa AB (Publ) and Vitrivax, Inc Reach Agreement in Principle

Nanexa AB (Publ) Launches NEX-22 Product Project to Address Huge Market

Nanexa AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.33 loss in 2Q 2021)

Nanexa AB (publ) Receives Extended GMP-Certificate for the New Pilot Plant

Less than half of directors are independent

Nanexa AB (publ), Annual General Meeting, Jun 09, 2022

Nanexa Receives Grant from VINNOVA for Study with Monoclonal Antibodies

Forecast to breakeven in 2023

Price target decreased to kr7.00

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanexa AB Announces That the Company's Preclinical Investigation

Price target decreased to kr7.00

High number of new directors

Nanexa Announces Inclusion of Patients in its Phase I Study with NEX-18

Second quarter 2021 earnings released

First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.22 loss in 1Q 2020)

Nanexa Appoints Jonas Fransson as Head of Pharmaceutical Development

New 90-day low: kr10.20

Full year 2020 earnings released: kr1.09 loss per share (vs kr0.88 loss in FY 2019)

Nanexa AB to Report Q1, 2021 Results on May 06, 2021

How Much Does Nanexa's (STO:NANEXA) CEO Make?

New 90-day low: kr10.25

Third quarter 2020 earnings released: kr0.18 loss per share

New 90-day high: kr13.40

New 90-day high - kr13.35

First half earnings released

New 90-day high - kr11.80

CEO 보상 분석

CEO

테뉴어